Zoetis Q2 Disappointment May Mark Valuation Floor

What happened

Zoetis reported flat Q2 2026 revenue with declining U.S. sales, though international and livestock segments showed resilience, prompting management to cut full-year guidance. This continues the deceleration highlighted in DeepValue's earlier WAIT report, which noted slowing companion animal growth and OA monoclonal antibody pressures. However, the stock's de-rating has pushed valuation to low multiples relative to history, and aggressive buybacks are providing support per the new Seeking Alpha analysis. The article's cautious Buy stance suggests the market may have overcorrected, but unresolved Librela safety concerns and competitive threats keep the risk-reward balanced. Overall, the worst may be priced in, but a return to premium growth is not yet evident.

Implication

For existing holders, the current valuation appears to offer limited downside, but patience is required until clearer signs of OA franchise recovery and competitive defense emerge. New investors might use further dips toward the $110 attractive entry level identified by DeepValue to build a position, while avoiding chasing rallies above $150. The 2026 guidance cut underscores that top-line growth remains fragile, so margin resilience and buyback execution are key supports for EPS. A failure to stabilize Librela/Solensia or accelerating share losses in Simparica/Apoquel would invalidate the cautious Buy thesis and push fair value toward the bear case of $100. Conversely, positive Phase IV data or successful Portela launch could re-rate the stock toward $155, offering an attractive asymmetric payoff at current prices.

Thesis delta

The thesis shifts from WAIT to cautious Buy as valuation has declined to reflect low-to-mid single-digit growth, reducing downside risk. However, the fundamental outlook remains unchanged: revenue growth is below historical norms and key OA risks persist, so the upgrade is valuation-driven rather than based on operational improvement. Investors should treat any rally toward $150 as a trim opportunity until organic growth reaccelerates above 8%.